

Mireia Diaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2088701/publications.pdf>

Version: 2024-02-01

52
papers

10,321
citations

159585

30
h-index

206112

48
g-index

53
all docs

53
docs citations

53
times ranked

11303
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary liver cancer: Worldwide incidence and trends. <i>Gastroenterology</i> , 2004, 127, S5-S16.	1.3	2,193
2	Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 453-459.	9.1	1,277
3	Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings. <i>Journal of Infectious Diseases</i> , 2010, 202, 1789-1799.	4.0	1,156
4	Against which human papillomavirus types shall we vaccinate and screen? the international perspective. <i>International Journal of Cancer</i> , 2004, 111, 278-285.	5.1	912
5	Epidemiology of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2005, 9, 191-211.	2.1	826
6	Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. <i>The Lancet Global Health</i> , 2016, 4, e453-e463.	6.3	580
7	Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention. <i>Journal of the National Cancer Institute</i> , 2006, 98, 303-315.	6.3	568
8	Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. <i>Vaccine</i> , 2006, 24, S26-S34.	3.8	427
9	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, H1-H31.	3.8	272
10	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, I1-I31.	3.8	261
11	Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. <i>British Journal of Cancer</i> , 2009, 100, 1191-1197.	6.4	173
12	Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. <i>Vaccine</i> , 2008, 26, 4080-4093.	3.8	164
13	Risk factors of invasive cervical cancer in Mali. <i>International Journal of Epidemiology</i> , 2002, 31, 202-209.	1.9	154
14	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 119-132.	27.6	154
15	Cervical Human Papillomavirus Infection in the Female Population in Barcelona, Spain. <i>Sexually Transmitted Diseases</i> , 2003, 30, 788-793.	1.7	126
16	Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. <i>British Journal of Cancer</i> , 2008, 99, 230-238.	6.4	111
17	Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. <i>Lancet Oncology</i> , The, 2011, 12, 1023-1031.	10.7	98
18	Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries. <i>Vaccine</i> , 2012, 30, F157-F167.	3.8	97

#	ARTICLE	IF	CITATIONS
19	Chlamydia trachomatis Infection in Female Partners of Circumcised and Uncircumcised Adult Men. American Journal of Epidemiology, 2005, 162, 907-916.	3.4	79
20	Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. International Journal of Cancer, 2012, 130, 2672-2684.	5.1	71
21	Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reproductive Health Matters, 2008, 16, 86-96.	1.2	68
22	New perspectives on screening and early detection of endometrial cancer. International Journal of Cancer, 2019, 145, 3194-3206.	5.1	58
23	Exploring the cost-effectiveness of HPV vaccination in Vietnam: Insights for evidence-based cervical cancer prevention policy. Vaccine, 2008, 26, 4015-4024.	3.8	53
24	Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region. Vaccine, 2008, 26, M17-M29.	3.8	51
25	Mathematical Models of Cervical Cancer Prevention in Latin America and the Caribbean. Vaccine, 2008, 26, L59-L72.	3.8	46
26	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, F1-F31.	3.8	40
27	Cost-effectiveness of human papillomavirus vaccination and screening in Spain. European Journal of Cancer, 2010, 46, 2973-2985.	2.8	38
28	Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in the Extended Middle East and North Africa (EMENA). Vaccine, 2013, 31, G65-G77.	3.8	37
29	Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in Sub-Saharan Africa. Vaccine, 2013, 31, F60-F72.	3.8	35
30	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, G1-G31.	3.8	33
31	Using HPV prevalence to predict cervical cancer incidence. International Journal of Cancer, 2013, 132, 1895-1900.	5.1	26
32	Cost-Effectiveness of Cervical Cancer Prevention in Central and Eastern Europe and Central Asia. Vaccine, 2013, 31, H71-H79.	3.8	18
33	Burden of Human Papillomavirus Infection and Related Diseases in Israel. Vaccine, 2013, 31, I32-I41.	3.8	17
34	Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain: the CRIVERVA study. BMC Public Health, 2017, 17, 194.	2.9	15
35	Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis. European Journal of Cancer Prevention, 2016, 25, 430-439.	1.3	11
36	Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses. Reports of Practical Oncology and Radiotherapy, 2018, 23, 484-494.	0.6	9

#	ARTICLE	IF	CITATIONS
37	Impact of model calibration on cost-effectiveness analysis of cervical cancer prevention. Scientific Reports, 2017, 7, 17208.	3.3	8
38	Screening of cervical cancer in Catalonia 2006-2012. Ecancermedicalsecience, 2015, 9, 532.	1.1	7
39	Defining a mutational signature for endometrial cancer screening and early detection. Cancer Epidemiology, 2019, 61, 129-132.	1.9	7
40	Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis. Journal of Medical Economics, 2019, 22, 1153-1159.	2.1	7
41	Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: A model-based cost-effectiveness analysis. Lung Cancer, 2021, 159, 153-161.	2.0	7
42	Effect of age-difference between heterosexual partners on risk of cervical cancer and human papillomavirus infection. Papillomavirus Research (Amsterdam, Netherlands), 2017, 3, 98-104.	4.5	6
43	Moving towards an organized cervical cancer screening: costs and impact. European Journal of Public Health, 2018, 28, 1132-1138.	0.3	6
44	An Integrated Approach for the Early Detection of Endometrial and Ovarian Cancers (Screenwide) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.5	6
45	Quantifying the under-reporting of uncorrelated longitudinal data: the genital warts example. BMC Medical Research Methodology, 2021, 21, 6.	3.1	4
46	The Epidemiology of Cervical Cancer. , 2012, , 63-83.		3
47	Screening for Cervical Cancer and Human Papillomavirus Vaccination in Israel: Recommendations. Vaccine, 2013, 31, 158-160.	3.8	2
48	El cribado del c�ncer de cuello de �tero en el Sistema P�blico de Salud de Catalu�a. Evaluaci�n y seguimiento durante el periodo 2006-2012. Progresos En Obstetricia Y Ginecologia, 2015, 58, 209-220.	0.0	2
49	Mo1701 Gastrointestinal Events After a Negative Colonoscopy in FIT-Positive Participants in an Organized, Population-Based Colorectal Cancer Screening Program. Gastroenterology, 2016, 150, S756.	1.3	1
50	Intrauterine device and cervical cancer: we need more evidence � Authors' reply. Lancet Oncology, The, 2011, 12, 1186-1187.	10.7	0
51	Intrauterine Device Use, Cervical Infection With Human Papillomavirus, and Risk of Cervical Cancer. Obstetrical and Gynecological Survey, 2012, 67, 353-355.	0.4	0
52	Online Cost-Effectiveness ANalysis (OCEAN): a user-friendly interface to conduct cost-effectiveness analyses for cervical cancer. BMC Medical Informatics and Decision Making, 2020, 20, 211.	3.0	0